Navigation Links
Cellular Dynamics International Announces Launch of Initial Public Offering
Date:7/10/2013

MADISON, Wis., July 10, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc., a developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications, today announced that it has commenced an initial public offering of 3,846,000 shares of common stock pursuant to a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission ("SEC").  In addition, the underwriters will have a 30-day option to purchase up to an additional 576,900 shares of common stock from the Company. The initial public offering price is currently expected to be between $12.00 and $14.00 per share of common stock.

The Company intends to use the net proceeds that it receives in the offering for research and product development activities; sales and marketing activities, including expansion of its sales force to support the ongoing commercialization of its products; property, plant and equipment, including the build-out of its laboratory in California, and intellectual property; and for working capital and other general corporate purposes.

J.P. Morgan Securities LLC is acting as sole book-running manager for the offering, and Cowen and Company, LLC and Leerink Swann LLC are acting as co-managers.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering, and the final prospectus when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone (866) 803-9204.

Forward-looking Statements

This press release includes "forward-looking statements," including with respect to the proposed initial public offering and the Company's intended use of proceeds. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control. The forward-looking information presented in this press release is not a guarantee of future events, and that actual events may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "plan," "seek," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise.

MEDIA CONTACTS:
Joleen Rau  
Senior Director, Marketing & Communications
Cellular Dynamics International, Inc.
608 310-5142
jrau@cellulardynamics.com 


'/>"/>
SOURCE Cellular Dynamics International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
2. Cellular Therapy and Cord Blood 2013 Market Report
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
5. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
6. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
7. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
8. Top Genetic and Cellular Researchers Honored at ASGCT 16th Annual Meeting
9. Exit discovered in cellular garbage truck
10. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
11. Cellular Biomedicine Group Provides Update and 2013 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... ... According to a recent report from the Environmental Security ... short- or long-term effects on benthic communities. , The ESTCP evaluated the ... Puget Sound Naval Shipyard & Intermediate Maintenance Facility in Bremerton, Washing. Data was ...
(Date:6/27/2017)... Iowa (PRWEB) , ... June 27, 2017 , ... ... technology license agreement whereby DuPont gains exclusive rights to the ERS patent portfolio ... ERS was formed to commercialize the foundational intellectual property (IP) of the CRISPR-Cas ...
(Date:6/26/2017)... Milwaukee, WI (PRWEB) , ... June 26, 2017 , ... ... today in role of Sales Director, focused on leading new business development and ensuring ... 10 years of experience in the food ingredient industry in technical, marketing and sales ...
(Date:6/26/2017)... ... June 26, 2017 , ... Two new members were elected to the ... 9, 2017: Jeremy Nowak, President, J Nowak Strategy and Michele Masucci, Ph.D., Vice President ... of Glen N. Gaulton and Kenneth L. Kring, and re-election of David P. Holveck ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):